Sirnaomics Raises $64 Million in Hong Kong IPO for RNA Therapies
publication date: Dec 30, 2021
Sirnaomics, a Maryland-Suzhou RNA biopharma, completed a $64 million IPO on the Hong Kong Exchange. Sirnaomics says it is the first company to report positive Phase IIa clinical results in oncology for an RNAi candidate. The company priced its IPO on the low end of the predicted range, but moved almost 20% higher in its first trading session, giving Siranomics a market cap of $900 million. Its product portfolio consists of 16 candidates for rare diseases and drugs with large patient populations including oncology, fibrosis, medical aesthetics, antiviral and cardiometabolic indications. More details....
Stock Symbol: (HK: 2257)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.